- Home
- IRWD
IRWD
Ironwood Pharmaceuticals Inc.
as 04-30-2025 4:00pm EST
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | N/A | IPO Year: | 2010 |
| Target Price: | $4.94 | AVG Volume (30 days): | 4.3M |
| Analyst Decision: | Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.01 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.59 - $8.45 | Next Earning Date: | 05-12-2025 |
| Revenue: | $351,410,000 | Revenue Growth: | -20.63% |
| Revenue Growth (this year): | -21.86% | Revenue Growth (next year): | -6.36% |
Stock Insider Trading Activity of Ironwood Pharmaceuticals Inc. (IRWD)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| John Minardo | IRWD | Chief Legal Officer | Feb 10 '25 | Sell | $1.76 | 38,938 | $68,530.88 | 408,132 | |
| MCCOURT Thomas A | IRWD | Chief Executive Officer | Feb 10 '25 | Sell | $1.76 | 139,064 | $244,752.64 | 1,160,634 | |
| Shetzline Michael | IRWD | SVP, CMO, Head-Res&Drug | Feb 10 '25 | Sell | $1.76 | 41,269 | $72,633.44 | 554,007 | |
| Silver Ronald | IRWD | Principal Accounting Officer | Feb 10 '25 | Sell | $1.76 | 12,048 | $21,204.48 | 279,655 | |
| Martini Gregory S. | IRWD | Chief Financial Officer | Feb 10 '25 | Sell | $1.76 | 12,052 | $21,211.52 | 183,810 |
Latest Ironwood Pharmaceuticals Inc. News
IRWD Breaking Stock News: Dive into IRWD Ticker-Specific Updates for Smart Investing
Business Wire
6 days ago
Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance
Business Wire
8 days ago
Ironwood Pharmaceuticals to Present Real-World Data at Digestive Disease Week® 2025 on Adoption of New Diagnosis Codes Among Short Bowel Syndrome Patients Who Are Dependent on Parenteral Support
Zacks
14 days ago
Biotech Stock Roundup: BMY Down on Study Failure, VERV Up on Study Data & More News
Zacks
15 days ago
Ironwood Shares Tank on Regulatory Update for Apraglutide
MT Newswires
15 days ago
Wells Fargo Downgrades Ironwood Pharmaceuticals to Equalweight From Overweight, Adjusts Price Target to $1 From $7
MT Newswires
15 days ago
Jefferies Downgrades Ironwood Pharmaceuticals to Hold From Buy, Adjusts Price Target to $0.70 From $8
Pharmaceutical Technology
16 days ago
Ironwood’s shares sink as FDA demands new trial for lead drug
MT Newswires
16 days ago
Sector Update: Health Care Stocks Rise Late Afternoon
Compare IRWD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IRWD Ironwood Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.